Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | YWHAZ | P63104 | 2/20 | 0.37 |
| ▸ | GRPR | P30550 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31461867 | 0.97 | KEAP1 (0.46) | KEAP1MEN1KMT2ACTSDBACE1 | |
| SCHEMBL29485603 | 0.95 | BACE1 (0.44) | KEAP1MEN1KMT2ACTSDBACE1 | |
| SCHEMBL29421961 | 0.94 | KEAP1 (0.44) | KEAP1MEN1KMT2ACTSDBACE1 | |
| SCHEMBL29421977 | 0.92 | KEAP1 (0.44) | KEAP1CTSDBACE1TERTMAPK8 | |
| SCHEMBL30930148 | 0.90 | MEN1 (0.41) | KEAP1MEN1KMT2ACTSDBACE1 | |
| SCHEMBL30930169 | 0.90 | MEN1 (0.41) | KEAP1MEN1KMT2ACTSDBACE1 | |
| SCHEMBL22922937 | 0.89 | KEAP1 (0.40) | KEAP1TERTMAPK8MAPK9MAPK10 | |
| SCHEMBL32678599 | 0.86 | KEAP1 (0.42) | KEAP1CTSDTERTMAPK8MAPK9 | |
| SCHEMBL32678598 | 0.86 | KEAP1 (0.42) | KEAP1CTSDTERTMAPK8MAPK9 | |
| SCHEMBL30974373 | 0.86 | FOLH1 (0.44) | KEAP1MEN1KMT2AFOLH1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2025-10-28 | — | — | US | disclosed |
| CN-114364691-B | Peptides as inhibitors of fibrotic matrix accumulation | 马克斯·普朗克科学促进学会 | 2023-12-12 | — | — | CN | disclosed |
| US-20220267378-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-08-25 | — | — | US | disclosed |
| EP-3996694-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-114364691-A | Peptides as inhibitors of fibrotic matrix accumulation | 马克斯·普朗克科学促进学会 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | GLS, AGXT, FN1 | KEAP1 1762/4885MEN1 1197/4885KMT2A 3918/4885 |
| US-20220267378-A1 | PEPTIDES AS INHIBITORS OF FIBROTIC MATRIX ACCUMULATION | INHA, GLS, AGXT | KEAP1 2478/4885MEN1 679/4885KMT2A 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.